medigraphic.com
Colegio de Medicina Interna de México.

2013, Number 3

<< Back Next >>

Med Int Mex 2013; 29 (3)

Serum Creatinine Levels and Heart Failure in Peritoneal Dialysis Patients

Flores-López EN, López-Alférez R, Arias-Ledesma G

Language: Spanish
References: 37
Page: 233-241
PDF size: 186.40 Kb.


ABSTRACT

Background: There is a close relation between renal failure and the clinical presentation of heart failure, but little has been reported about the possible markers showing it.
Objective: To determine the functional class of heart failure patients under treatment with peritoneal dialysis and its relation to creatinine concentrations.
Patients and method: Retrospective, cross-sectional, and descriptive study conducted in 90 chronic renal failure patients on replacement therapy of renal function by peritoneal dialysis from the Nephrology Department at the General Hospital Zone 58 of the Mexican Social Security Institute. Serum creatinine levels were measured and their concentrations were related to the clinical manifestation of heart failure. The Framingham criteria were used to determine the functional class. The analysis was multiple variance and linear regression using SPSS.
Results: 50% of the studied patients had positive Framingham criteria for heart failure, 41 patients with functional class I, 22 with functional class II, and 27 with functional class III. Heart failure was 19.6 times higher with creatinine under 10 mg/dL, p ‹0.001, 95% CI: 6.6-58.1. Patients with Framingham criteria for heart failure and creatinine concentrations of less than 10 mg/dL were 0.97 more related to functional class II and III p ‹0.01, 95% CI: 0.25-3.24. Uric acid, hemoglobin and hematocrit were other statistically significant variables for heart failure.
Conclusions: Creatinine may represent a factor for heart failure. However, in peritoneal dialysis patients this parameter cannot be considered a direct factor because no other variables, like medications and nutritional state, were associated with each patient. Therefore, our main contribution lies in pointing out the need for further studies in Mexican patients considering all clinical and pharmacological conditions for obtaining more objective results.


REFERENCES

  1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. N Eng J Med 2004;351:1296-305. [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/15385656

  2. US Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, [en línea] Bethesda, MD, 2011; [accesado 18 Abr 2012] Disponible en: http://www.usrds.org/adr.htm. Publications based upon USRDS data reported here or supplied upon request must include this citation and the following notice: The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. government.

  3. Paniagua R, Ramos A, Fabian R, Lagunas J, Amato D. Chronic kidney disease and dialysis in Mexico. Perit Dial Int 2007;27:405-9. [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/ 17602147

  4. COHS, Consultores en Ciencias Humanas. El tratamiento renal sustitutivo en España, Informe de diálisis y trasplante, 2005 [en línea] Santander: Sociedad Española de Nefrología; 2009 [accesado 19 Abr 2012] Disponible en: http://www.senefro. org/modules/webstructure/files/el_tratamiento_renal_sustitutivo_ en_espaa.pdf?check_idfile=2458

  5. Simal F, Martín Escudero JC, Bellido J, Arzua D, Mena FJ, González Melgosa I, at al. Prevalencia de la enfermedad renal crónica leve y moderada en población general. Nefrologia 2004;24:329-32, 334, 336-7. [PubMed] http://www.ncbi.nlm. nih.gov/pubmed/15455492

  6. Treviño-Becerra A, Maimone MA. Peritoneal dialysis in the developing world: the Mexican scenario. Artif Organs 2002;26:750-2. [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/ 12197926

  7. Garcia-Garcia G, Monteon-Ramos JF, Garcia-Bejarano H, Gomez-Navarro B, Reyes IH, Lomeli AM, et al. Renal replacement therapy among disadvantaged populations in Mexico: a report from the Jalisco Dialysis and Transplant Registry (REDTJAL). Kidney Int Suppl 2005:S58-61. [PubMed] http:// www.ncbi.nlm.nih.gov/pubmed/16014102

  8. Cusumano A, Garcia GG, Di Gioia C, Hermida O, Lavorato C; Latin American Registry of Dialysis and Transplantation: The Latin American Dialysis and Transplantation Registry (RLDT) annual report 2004. Ethn Dis 2006;16(2 Suppl 2):S2-10-3. [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/16774002

  9. Cueto-Manzano AM, Rojas-Campos E. Status of renal replacement therapy and peritoneal dialysis in Mexico. Perit Dial Int 2007;27:142-8. [PubMed] http://www.ncbi.nlm.nih.gov/ pubmed/17299147

  10. Amsalem Y, Garty M, Schwartz R, Sandach A, Behar S, Caspi A, et al. Prevalence and significance of unrecognized renal insufficiency in patients with heart failure. Eur Heart J 2008;29:1029-36 [PubMed] http://www.ncbi.nlm.nih.gov/ pubmed/18339607

  11. Belziti CA, Bagnati R, Ledesma P, Vulcano N, Fernández S. Worsening renal function in patients admitted with acute decompensated heart failure: incidence, risk factors and prognostic implications. Rev EspCardiol 2010;63:294-302. [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/20196990

  12. Smith GL, Shlipak MG, Havranek EP, Masoudi FA, McClellan WM, Foody JM, et al. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005;111:1270-7. [PubMed] http://www.ncbi.nlm.nih.gov/ pubmed/15769768

  13. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B; POSH Investigators. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006;27:1216-22. Epub 2006 Apr 19. [PubMed] http://www.ncbi.nlm.nih.gov/ pubmed/16624834

  14. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007;13:599-608. [PubMed] http://www.ncbi.nlm.nih.gov/ pubmed/17923350

  15. Volkova N, McClellan W, Soucie JM, Schoolwerth A. Racial disparities in the prevalence of cardiovascular disease among incident end-stage renal disease patients. Nephrol Dial Transplant 2006;21:2202-9. Epub 2006 Mar 7. [PubMed] http://www. ncbi.nlm.nih.gov/pubmed/16522661

  16. Parikh NI, Hwang SJ, Larson MG, Levy D, Fox CS. Chronic kidney disease as a predictor of cardiovascular disease (from the Framingham Heart Study). Am J Cardiol 2008;102:47-53. [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/18572034

  17. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, et al. Cardiovascular disease in patients with chronic kidney disease: Getting to the heart of the matter. Am J Kidney Dis 2001;38:1398-407. [PubMed] http://www.ncbi.nlm.nih.gov/ pubmed/11728982

  18. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetinalfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098. [PubMed] http:// www.ncbi.nlm.nih.gov/pubmed/17108343

  19. Zalunardo N, Levin A. Anemia and the heart in chronic kidney disease SeminNephrol 2006;26:290-5. [PubMed] http://www. ncbi.nlm.nih.gov/pubmed/16949467

  20. Sánchez-Torrijos J, Gudín-Uriel M, Nadal-Barangé M, Jacas-Osborn V, Trigo-Bautista A, Giménez-Alcalá M, et al. Prognostic Value of Discharge Hemoglobin Level in Patients Hospitalized for Acute Heart Failure. Rev EspCardiol 2006;59:1276-1282. [PubMed] http://www.ncbi.nlm.nih.gov/ pubmed/17194423

  21. Virani SA, Khosla A, Levin A. Chronic kidney disease, hear failure and anemia. Can J Cardiol 2008;24Suppl B:22B-4B. [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/18629385

  22. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-36. [PubMed] http:// www.ncbi.nlm.nih.gov/pubmed/12089390

  23. Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006;113(23):2713- 23. Epub 2006 Jun 5. [PubMed] http://www.ncbi.nlm.nih.gov/ pubmed/16754803

  24. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-90. [Pub- Med] http://www.ncbi.nlm.nih.gov/pubmed/7752588

  25. Wang AY, Wang M, Lam CW, Chan IH, Lui SF, Sanderson JE. Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis. Clin J Am Soc Nephrol 2011;6:805-12. [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/21212423

  26. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-6. [PubMed] http://www. ncbi.nlm.nih.gov/pubmed/5122894

  27. Jimeno Sainz A, Gil V, Merino J, García M, Jordán A, Guerrero L. Validez de los criterios clínicos de Framingham para el diagnóstico de insuficiencia cardiaca sistólica. Rev Clin Esp 2006;206:495-8. [PubMed] http://www.ncbi.nlm.nih.gov/ pubmed/17203567

  28. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am CollCardiol 2006;47:1987-96. Epub 2006 Apr 24. [PubMed] http://www. ncbi.nlm.nih.gov/pubmed/16697315

  29. Mann JF, Gerstein HC, Yi QL, Franke J, Lonn EM, Hoogwerf BJ, et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 2003;42:936-42. [PubMed] http://www.ncbi.nlm. nih.gov/pubmed/14582037

  30. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001;12:218-25. [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/11158211

  31. Butler R, Morris AD, Bellch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746-751. [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/10720589

  32. Leyva F, Anker S, Swan JW, Godsland IF, Wingrove CS, Chua TP, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18: 858-865,. [PubMed] http://www.ncbi.nlm.nih.gov/ pubmed/9152657

  33. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002;40:355- 360. [PubMed] http://www.ncbi.nlm.nih.gov/pubmed/12215479

  34. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. A role of uric acid in the progression of renal disease. J Am SocNephrol 2002;13:2888- 2897. [PubMed] http://www. ncbi.nlm.nih.gov/pubmed/12444207

  35. Caravaca F, Martín MV, Barroso S, Cancho B, Arrobas M, Luna E, et al. Niveles de ácido úrico y proteína C reactiva en pacientes con insuficiencia renal crónica. Nefrologia. 2005;25:645-54. [PubMed] http://www.ncbi.nlm.nih.gov/ pubmed/16514905

  36. Ateş K, Nergizoğlu G, Keven K, Sen A, Kutlay S, Ertürk S, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001;60:767-776. [PubMed] http:// www.ncbi.nlm.nih.gov/pubmed/11473661

  37. Martínez-Gallardo R, Ferreira-Morong F, García-Pino G, Cerezo-Arias I, Hernández-Gallego R, Caravaca F. Congestive heart failure in patients with advanced chronic kidney disease: association with pre-emptive vascular access placement. Nefrologia 2012;32:206-12.




2020     |     www.medigraphic.com